Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1980 Apr;132(4):357–360.

Inhibition of glucagon secretion by diphenylhydantoin in a patient with glucagonoma.

T Machina, R Marcus, S R Levin
PMCID: PMC1272091  PMID: 6992459

Full text

PDF
357

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMATUZIO D. S., STUTZMAN F. L., VANDERBILT M. J., NESBITT S. Interpretation of the rapid intravenous glucose tolerance test in normal individuals and in mild diabetes mellitus. J Clin Invest. 1953 May;32(5):428–435. doi: 10.1172/JCI102755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BUCHTHAL F., SVENSMARK O., SCHILLER P. J. Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960 Jun;2:624–630. doi: 10.1001/archneur.1960.03840120030004. [DOI] [PubMed] [Google Scholar]
  3. FRANDSEN J. Sygebehandlingen. Ugeskr Laeger. 1956 Nov 8;118(45):1338–1342. [PubMed] [Google Scholar]
  4. GRODSKY G. M., FORSHAM P. H. An immunochemical assay of total extractable insulin in man. J Clin Invest. 1960 Jul;39:1070–1079. doi: 10.1172/JCI104122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gerich J. E., Charles M. A., Levin S. R., Forsham P. H., Grodsky G. M. In vitro inhibition of pancreatic glucagon secretion by diphenylhydantoin. J Clin Endocrinol Metab. 1972 Dec;35(6):823–824. doi: 10.1210/jcem-35-6-823. [DOI] [PubMed] [Google Scholar]
  6. Hofeldt F. D., Dippe S. E., Levin S. R., Karam J. H., Blum M. R., Forsham P. H. Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes. 1974 Mar;23(3):192–198. doi: 10.2337/diab.23.3.192. [DOI] [PubMed] [Google Scholar]
  7. Knopp R. H., Scheinin J. C., Freinkel N. Diphenylhydantoin and an insulin-secreting islet adenoma. Arch Intern Med. 1972 Dec;130(6):904–908. [PubMed] [Google Scholar]
  8. Levin S. R., Booker J., Jr, Smith D. F., Grodsky G. M. Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas. J Clin Endocrinol Metab. 1970 Mar;30(3):400–401. doi: 10.1210/jcem-30-3-400. [DOI] [PubMed] [Google Scholar]
  9. Levin S. R., Kasson B. G., Driessen J. F. Adenosine triphosphatases of rat pancreatic islets: comparison with those of rat kidney. J Clin Invest. 1978 Sep;62(3):692–701. doi: 10.1172/JCI109177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levin S. R., Reed J. W., Ching K. N., Davis J. W., Blum M. R., Forsham P. H. Diphenylhydantoin. Its use in detecting early insulin secretory defects in patients with mild glucose intolerance. Diabetes. 1973 Mar;22(3):194–201. doi: 10.2337/diab.22.3.194. [DOI] [PubMed] [Google Scholar]
  11. Lightman S. L., Bloom S. R. Cure of insulin-dependent diabetes mellitus by removal of a glucagonoma. Br Med J. 1974 Mar 2;1(5904):367–368. doi: 10.1136/bmj.1.5904.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lips C. J., van der Sluys V., van der Donk J. A., van Dam R. H. Common precursor molecule as origin for the ectopic-hormone-producing-tumour syndrome. Lancet. 1978 Jan 7;1(8054):16–18. doi: 10.1016/s0140-6736(78)90361-6. [DOI] [PubMed] [Google Scholar]
  13. Malherbe C., Burrill K. C., Levin S. R., Karam J. H., Forsham P. H. Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med. 1972 Feb 17;286(7):339–342. doi: 10.1056/NEJM197202172860702. [DOI] [PubMed] [Google Scholar]
  14. Mallinson C. N., Bloom S. R., Warin A. P., Salmon P. R., Cox B. A glucagonoma syndrome. Lancet. 1974 Jul 6;2(7871):1–5. doi: 10.1016/s0140-6736(74)91343-9. [DOI] [PubMed] [Google Scholar]
  15. Mortimer C. H., Tunbridge W. M., Carr D., Yeomans L., Lind T., Coy D. H., Bloom S. R., Kastin A., Mallinson C. N., Besser G. M. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet. 1974 Apr 20;1(7860):697–701. doi: 10.1016/s0140-6736(74)92903-1. [DOI] [PubMed] [Google Scholar]
  16. Pelkonen R., Taskinen M. R. Effect of diphenylhydantoin on plasma-insulin in insulinoma. Lancet. 1973 Mar 17;1(7803):604–605. doi: 10.1016/s0140-6736(73)90747-2. [DOI] [PubMed] [Google Scholar]
  17. Raskin P., Unger R. H. Effects of exogenous hyperglucagonemia in insulin-treated diabetics. Diabetes. 1977 Nov;26(11):1034–1039. doi: 10.2337/diab.26.11.1034. [DOI] [PubMed] [Google Scholar]
  18. Riddle M. C., Golper T. A., Fletcher W. S., Ensinck J. W., Smith P. H. Glucagonoma syndrome in a 19-year-old woman. West J Med. 1978 Jul;129(1):68–72. [PMC free article] [PubMed] [Google Scholar]
  19. Srikant C. B., Unger R. H. Evidence for the presence of glucagon-like immunoreactivity (GLI) in the pancreas. Endocrinology. 1976 Dec;99(6):1655–1658. doi: 10.1210/endo-99-6-1655. [DOI] [PubMed] [Google Scholar]
  20. Tiengo A., Fedele D., Marchiori E., Nosadini R., Muggeo M. Suppression and stimulation mechanisms controlling glucagon secretion in a case of islet-cell tumor producing glucagon, insulin, and gastrin. Diabetes. 1976 May;25(5):408–412. doi: 10.2337/diab.25.5.408. [DOI] [PubMed] [Google Scholar]
  21. Valverde I., Rigopoulou D., Marco J., Faloona G. R., Unger R. H. Molecular size of extractable glucagon and glucagon-like immunoreactivity (GLI) in plasma. Diabetes. 1970 Sep;19(9):624–629. doi: 10.2337/diab.19.9.624. [DOI] [PubMed] [Google Scholar]
  22. WASHKO M. E., RICE E. W. Determination of glucose by an improved enzymatic procedure. Clin Chem. 1961 Oct;7:542–545. [PubMed] [Google Scholar]
  23. Weir G. C., Horton E. S., Aoki T. T., Slovik D., Jaspan J., Rubenstein A. H. Secretion by glucagonomas of a possible glucagon precursor. J Clin Invest. 1977 Feb;59(2):325–330. doi: 10.1172/JCI108644. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES